Search

Savara Inc

Gesloten

SectorGezondheidszorg

5.36

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

5.36

Max

5.38

Belangrijke statistieken

By Trading Economics

Inkomsten

-2.9M

-40M

EPS

-0.16

Werknemers

70

EBITDA

-3M

-40M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+108.57% upside

Dividenden

By Acuity

Volgende Winsten

10 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-67M

1.1B

Vorige openingsprijs

5.36

Vorige sluitingsprijs

5.36

Nieuwssentiment

By Acuity

50%

50%

132 / 339 Rangschikking in Healthcare

Savara Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 sep 2026, 19:26 UTC

Savara Inc shares are higher today, trading within a narrow range. The stock is currently near the lower end of its one-month range.

3 sep 2026, 20:02 UTC

Savara Inc shares are lower during Thursday's session, retracing from an earlier peak amid rising jobless claims that may affect Federal Reserve policy.

2 sep 2026, 20:08 UTC

Savara Inc. shares are higher today, driven by a significant upward trend in the Biotechnology sub-sector. No specific company news was identified.

1 sep 2026, 19:36 UTC

Savara Inc. shares are lower today, continuing a decline since Monday. The stock remains below its 20-day moving average amid rising inflation concerns.

31 aug 2026, 22:01 UTC

Savara Inc. shares rose in after-market trading, advancing since Monday's close, despite earlier pulling back from a session high. No specific news was identified.

28 aug 2026, 21:02 UTC

In after-market trading, Savara Inc. has increased following a flat start, indicating upward momentum despite remaining below its 20-day moving average.

27 aug 2026, 23:56 UTC

Savara Inc shares are higher in after-market trading, despite no specific news. Broader market sentiment remains mixed amid ongoing inflation concerns and upcoming Fed guidance.

25 aug 2026, 19:16 UTC

Event

Savara Inc announced presentations at the ERS Congress, yet shares are trading lower today, reflecting a slight decline since Monday's close.

24 aug 2026, 22:01 UTC

News

Savara Inc. will present Phase 3 trial results for molgramostim at the European Respiratory Society Congress in 2026. Shares are higher in after-market trading.

21 aug 2026, 19:36 UTC

News

Savara Inc. granted inducement awards to eight new employees, including options for 74,500 shares. Shares are higher since Thursday's close.

20 aug 2026, 20:02 UTC

Savara Inc shares are lower amid a broader market downturn, influenced by disappointing sales growth from major retailers like Walmart Inc. Trading volume remains unusually high.

19 aug 2026, 19:26 UTC

Savara Inc is trading higher today, maintaining upward momentum since Tuesday's close. The stock moved from a session low to a pre-market high.

18 aug 2026, 23:01 UTC

Savara Inc shares declined in after-market trading, falling below their 20-day moving average after an earlier surge. No specific news was identified to explain the volatility.

17 aug 2026, 19:46 UTC

Savara Inc is trading lower today, retracing from earlier gains and near the lower end of its one-month range. No specific news was identified.

14 aug 2026, 19:44 UTC

Savara Inc shares are higher today amid increased trading volume. No specific company news was identified to explain the price movement.

13 aug 2026, 20:02 UTC

Savara Inc shares are lower today, continuing a decline since Wednesday. The stock saw high trading volume amid no specific news.

12 aug 2026, 19:56 UTC

News

Savara Inc. shares are higher following Citizens' reaffirmation of its Outperform rating and $10 price target ahead of the MOLBREEVI PDUFA date.

11 aug 2026, 19:11 UTC

Savara Inc shares are lower today amid unusually high market volume. No specific news was identified to explain the decline.

10 aug 2026, 23:01 UTC

Savara Inc shares are lower in after-market trading, showing notable volatility without any specific news to explain the decline.

7 aug 2026, 19:36 UTC

Savara Inc is trading higher, benefiting from broader market gains following a weaker-than-expected jobs report that may delay Federal Reserve interest rate hikes.

6 aug 2026, 20:06 UTC

Savara Inc shares are higher today, recovering from earlier declines and trading above their 20-day moving average. No specific news was identified for the move.

5 aug 2026, 19:36 UTC

News

Savara Inc. shares are higher as the company advances its Biologics License Application for molgramostim, with a key PDUFA date approaching.

4 aug 2026, 23:01 UTC

Savara Inc shares are trading higher in after-market hours, showing significant volatility with no specific news identified to explain the price movement.

3 aug 2026, 20:06 UTC

Savara Inc is declining today, diverging from recent higher closes. Broader market indices, including the S&P 500 and Nasdaq 100, are gaining.

31 jul 2026, 20:06 UTC

Event

Savara Inc shares are lower despite the European Patent Office granting a patent for MOLBREEVI, effective through March 2041. The stock remains near its one-month low.

30 jul 2026, 20:09 UTC

Event

Savara Inc shares rise after the European Patent Office grants a patent for MOLBREEVI, providing protection until March 2041.

29 jul 2026, 19:47 UTC

Savara Inc's shares are lower, marking five consecutive sessions of decline. Broader market performance is mixed as traders await the Federal Reserve's interest rate decision.

28 jul 2026, 19:16 UTC

Savara Inc. shares are lower today amid ongoing price weakness. Broader markets like the FTSE 100 and DAX are showing resilience despite this decline.

27 jul 2026, 14:02 UTC

Savara Inc shares are higher during Monday's session, reaching their peak at 9:30 AM ET. No specific news was identified to explain the movement.

24 jul 2026, 20:02 UTC

Savara Inc shares are lower today, continuing a decline since Thursday amid high market volume. Broader market sentiment is affected by recent oil price volatility.

Peer Vergelijking

Prijswijziging

Savara Inc Prognose

Koersdoel

By TipRanks

108.57% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 11.2 USD  108.57%

Hoogste 16 USD

Laagste 9 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Savara Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Sentiment

By Acuity

132 / 339 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
help-icon Live chat